Loading...

Kadmon Holdings, Inc.

KDMN•NYSE
Healthcare
Biotechnology
$9.50
$0.00(0.00%)

Kadmon Holdings, Inc. (KDMN) Stock Overview

Explore Kadmon Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.9/100

Key Financials

Market Cap0
P/E Ratio-14.50
EPS (TTM)$-0.71
ROE-0.77%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 Month$10.36
3 Months$13.41
1 Year Target$4.15

KDMN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Kadmon Holdings, Inc. (KDMN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 0.00, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $4.15.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -14.50 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

0.00RSI (14)
0.00MACD
0.00ADX
Stats data is not available for KDMNStats details for KDMN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for KDMNAnalyst Recommendations details for KDMN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.

CEO

Harlan Waksal

Employees

127

Headquarters

450 E 29th St, New York City, NY

Founded

2016

Frequently Asked Questions

;